TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ISOVUE-128

IOPAMIDOL
Approved 1985-12-31
Jump to: Indications Approvals Trials Competitors Safety Patents
12
Indications
--
Phase 3 Trials
40
Years on Market

Details

Status
Discontinued
First Approved
1985-12-31
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

BRACCO
Active Ingredient: IOPAMIDOL

ISOVUE-128 Approval History

Loading approval history...

What ISOVUE-128 Treats

12 FDA approvals

Originally approved for its first indication in 1985 . Covers 12 distinct patient populations.

  • Other (12)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ISOVUE-128 FDA Label Details

Pro

ISOVUE-128 Patents & Exclusivity

Exclusivity: Oct 2028

Exclusivity

I-975 Until Oct 2028
I-975 Until Oct 2028
I-975 Until Oct 2028
I-975 Until Oct 2028
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA018735 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.